To assess potential therapeutic effects of TMAO in vivo, we carried out glucose tolerance and insulin secretion tests in CHD- and HFD-fed mice treated by chronic subcutaneous infusion of this compound (Figure 5). This evidence concerns the gene INS and coronary artery disorder.